"We believe that the case-control study of coronary artery disease published by Assimes et al., is not a replication study of the published prospective studies of KIF6 Trp719Arg, which involved rigorous prospective and randomized controlled trial designs," said Thomas White, Ph.D., Chief Scientific Officer at Celera. "Moreover, Celera and others have previously reported1-4 the finding that in case-control studies there was no association between KIF6 and nonfatal MI or CAD, and thus we see little that is new or relevant to the association between KIF6 and statin benefit."
They also pointed out a conflict of interest in the JACC paper: multiple authors work for a competing genetics company.
No comments:
Post a Comment